You have 9 free searches left this month | to do more
Showing 1 - 25 of
3,305 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
BMS-986253 in Myelodysplastic Syndromes
Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes - 2015
Completed
  • Myelodysplastic Syndromes
    • (no location specified)
    2022-01-21
    Jan 21, 2022
    C
    Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes - 2009
    Completed
    • Leukemias
    • Myelodysplastic Syndromes
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    2021-12-07
    Dec 7, 2021
    T
    Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes
    No longer available
    • Myelodysplastic Syndromes
    • (no location specified)
    2021-09-08
    Sep 8, 2021
    R
    Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
    Not yet recruiting
    • Low Risk Myelodysplastic Syndromes
    • R906289 Monosodium (R289 Na)
    • (no location specified)
    2022-03-25
    Mar 25, 2022
    U
    A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
    Active, not recruiting
    • Myelodysplastic Syndromes
    • Chronic Myelomonocytic Leukemia
    • Rochester, New York
      University of Rochester
    2022-01-04
    Jan 4, 2022
    W
    Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
    Active, not recruiting
    • Myelodysplastic Syndromes
    • Saint Louis, Missouri
      Washington University School of Medicine
    2022-03-23
    Mar 23, 2022
    A
    APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
    Recruiting
    • MDS
    • Myelodysplastic Syndromes
    • APR-548 + Azacitidine
    • Tampa, Florida
    • +3 more
    2022-01-18
    Jan 18, 2022
    M
    Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) - 2021
    Withdrawn
    • Myelodysplastic Syndromes
    • Bronx, New York
      Montefiore Medical Center
    2021-09-15
    Sep 15, 2021
    Y
    CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure. - 2021
    Withdrawn
    • MDS
    • New Haven, Connecticut
      Yale University; Smilow Cancer Center
    2022-01-06
    Jan 6, 2022
    M
    Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes - 2021
    Completed
    Has Results
    • Myelodysplastic Syndromes
    • selinexor (KPT-330)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    2022-02-11
    Feb 11, 2022
    T
    A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
    Withdrawn
    • Myelodysplastic Syndromes (MDS)
    • (no location specified)
    2021-09-23
    Sep 23, 2021
    O
    Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
    Active, not recruiting
    • Lower-risk Myelodysplastic
    • Tokyo, Japan
      NTT Medical Center Tokyo
    2022-01-14
    Jan 14, 2022
    M
    Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
    Active, not recruiting
    • Myelodysplastic Syndromes
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    2021-05-07
    May 7, 2021
    C
    TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid - 2021
    Completed
    • Myelodysplastic Syndromes
    • +2 more
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    2021-08-04
    Aug 4, 2021
    A
    ACE-536 Extension Study - Myelodysplastic Syndromes - 2020
    Completed
    • Myelodysplastic Syndromes
    • Dresden, Germany
      Acceleron Investigative Site
    2021-04-29
    Apr 29, 2021
    S
    Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
    Not yet recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • (no location specified)
    2021-11-29
    Nov 29, 2021
    W
    CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy - 2018
    Terminated
    • Previously Treated Myelodysplastic Syndromes
    • 6,8-bis(benzylthio)octanoic acid
    • Winston-Salem, North Carolina
      Comprehensive Cancer Center of Wake Forest University
    2021-07-01
    Jul 1, 2021
    G
    Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
    Withdrawn
    • Myelodysplastic Syndromes
    • Acute Myeloid Leukemia
    • Huixquilucan, Estado De México, Mexico
      Grupo Cooperativo de Hemopatías Malignas
    2021-07-05
    Jul 5, 2021
    S
    LBH589 in Refractory Myelodysplastic Syndromes (MDS) - 2011
    Terminated
    Has Results
    • Myelodysplastic Syndromes (MDS)
    • Fort Myers, Florida
    • +6 more
    2021-11-18
    Nov 18, 2021
    M
    Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
    Active, not recruiting
    • High Risk Myelodysplastic Syndrome
    • Houston, Texas
      M D Anderson Cancer Center
    2022-02-02
    Feb 2, 2022
    C
    CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
    Recruiting
    • Refractory Acute Myeloid Leukemia
    • +2 more
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    2022-03-15
    Mar 15, 2022
    U
    Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
    Recruiting
    • High Grade Myelodysplastic Syndromes
    • Aurora, Colorado
      Universtiy of Colorado Denver
    2021-10-19
    Oct 19, 2021
    A
    A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes - 2020
    Completed
    • Myelodysplastic Syndrome (MDS)
    • AMV564 14-Day CIV
    • Duarte, California
    • +4 more
    2021-10-11
    Oct 11, 2021
    T
    Follow-up Study of ICUS and CCUS Patients
    Enrolling by invitation
    • Myelodysplastic Syndromes
    • Observation and necessary supportive care
    • Suzhou, Jiangsu, China
      The First Affliated Hospital of Soochow University
    2022-03-16
    Mar 16, 2022